A Randomized Placebo-Controlled Trial of d-Cycloserine to Enhance Exposure Therapy for Posttraumatic Stress Disorder
Biological Psychiatry, 04/16/2012De Kleine RA et al.
The present study found preliminary support for the augmentation of exposure therapy with d–cycloserine (DCS), specifically for patients with more severe Posttraumatic stress disorder (PTSD) needing longer treatment.
In a randomized, double–blind, placebo–controlled trial the authors administered 50 mg DCS or placebo 1 hour before each exposure session to 67 mixed trauma patients, recruited from regular referrals, with a primary PTSD diagnosis satisfying DSM–IV criteria.
Although DCS did not enhance overall treatment effects, the participants having received DCS did show a stronger treatment response.
Exploratory session–by–session analyses revealed that DCS yielded higher symptom reduction in those participants that had more severe pretreatment PTSD and needed longer treatment.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.